PDL BioPharma, Inc.
PDLIV
NASDAQ
Recommendation
Prev Close
--
Volume
--
Avg Vol (90D)
--
Market Cap
--
Dividend & Yield
--
52-Week Range
-- - --
P/E (TTM)
--
EPS (TTM)
| 08/31/2020 | 06/30/2020 | 03/31/2020 | 12/31/2019 | 09/30/2019 | |
|---|---|---|---|---|---|
| Revenue | 19.73M | 27.76M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.73M | 27.76M | -- | -- | -- |
| Cost of Revenue | 9.28M | 14.05M | -- | -- | -- |
| Gross Profit | 10.45M | 13.71M | -- | -- | -- |
| SG&A Expenses | 38.37M | 49.98M | -- | -- | -- |
| Depreciation & Amortization | 944.00K | 1.27M | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.16M | 74.17M | -- | -- | -- |
| Operating Income | -33.44M | -46.41M | -- | -- | -- |
| Income Before Tax | -50.66M | -65.61M | -- | -- | -- |
| Income Tax Expenses | -10.01M | -13.15M | -- | -- | -- |
| Earnings from Continuing Operations | -40.65 | -52.46 | -- | -- | -- |
| Earnings from Discontinued Operations | -96.52M | -102.68M | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 585.00K | 767.00K | -- | -- | -- |
| Net Income | -136.58M | -154.37M | -- | -- | -- |
| EBIT | -33.44M | -46.41M | -- | -- | -- |
| EBITDA | -31.06M | -43.09M | -- | -- | -- |
| EPS Basic | -1.58 | -1.31 | -- | -- | -- |
| Normalized Basic EPS | -0.18 | -0.26 | -- | -- | -- |
| EPS Diluted | -1.59 | -1.32 | -- | -- | -- |
| Normalized Diluted EPS | -0.18 | -0.26 | -- | -- | -- |
| Average Basic Shares Outstanding | 357.44M | 470.42M | -- | -- | -- |
| Average Diluted Shares Outstanding | 473.34M | 470.42M | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -0.01% | -0.01% | -- | -- | -- |